— Know what they know.
Not Investment Advice

ADPT NASDAQ

Adaptive Biotechnologies Corporation
1W: +5.2% 1M: -2.3% 3M: -8.8% YTD: -12.8% 1Y: +48.2% 3Y: +123.7% 5Y: -59.8%
$13.88
+0.01 (+0.07%)
 
Weekly Expected Move ±6.5%
$11 $12 $13 $14 $14
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 47 · $2.2B mcap · 154M float · 1.25% daily turnover · Short 33% of daily vol

Cash Flow Trends

Operating Cash Flow
-$46M +51.7% ▲
Capital Expenditures
$3M +19.2% ▲
5Y CAGR: -30.9%
Free Cash Flow
-$49M +50.5% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$22M +230.2% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$207M-$200M-$225M-$160M-$59M
Depreciation & Amort.$21M$28M$22M$19M$0
Stock-Based Comp.$0$0$0$54M$51M
Change in Working Capital-$57M-$72M-$46M-$17M-$58M
Other Non-Cash Items$50M$60M$93M$9M$20M
Operating Cash Flow-$193M-$184M-$156M-$95M-$46M
— Investing Activities —
Capital Expenditures-$62M-$16M-$11M-$4M-$3M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$317M-$279M-$430M-$244M-$182M
Investment Sales$560M$298M$570M$326M$223M
Other Investing$0$0$0$0$0
Investing Cash Flow$181M$3M$130M$78M$38M
— Financing Activities —
Net Debt Issuance$0$124M$0$0$0
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$429K$0$0$0$0
Financing Cash Flow$27M$132M$2M$241K$30M
Net Change in Cash$16M-$49M-$25M-$17M$22M
Cash End of Period$139M$90M$65M$51M$73M
Free Cash Flow-$254M-$200M-$167M-$99M-$49M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms